Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rexlemestrocel-L + hyaluronic acid (Mesoblast Ltd)
- Development stage
- Unknown
- Lead developer
- Mesoblast
- Modality
- Cell Therapies
- Administration
- Percutaneous
01
Overview
Rexlemestrocel-L + hyaluronic acid (MPC-06-ID) is an investigational cell-based combination therapy developed by **Mesoblast** for the treatment of chronic low back pain (CLBP) associated with moderate degenerative disc disease (DDD). The therapy consists of allogeneic (donor-derived) mesenchymal precursor cells (MPCs) delivered via a single intradiscal injection using a hyaluronic acid (HA) carrier, which serves as a scaffold. The MPCs are thought to function through paracrine signaling, secreting factors that reduce inflammation by inhibiting pro-inflammatory cytokines like TNF and IL-1, promoting the synthesis of proteoglycans and collagen to repair the disc matrix, and inhibiting nerve ingrowth to provide analgesia. The product has completed Phase 3 clinical evaluation.
- Other names
- mesenchymal precursor cells + hyaluronanMPCs + HArexlemestrocel-L + HA
Beyond the preview
Go deeper on rexlemestrocel-L + hyaluronic acid (Mesoblast Ltd).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rexlemestrocel-L + hyaluronic acid (Mesoblast Ltd).